What is the current market size?

The Rapid Saliva Testing Devices market size reached USD 1.2 billion in 2023, driven by pandemic-related demand and non-invasive testing adoption.

What is the expected growth rate?

The market is projected to grow at a 5.5% CAGR from 2024 to 2030, with point-of-care diagnostics and chronic disease monitoring fueling expansion.

What are the key market drivers?

Key drivers include non-invasive testing preferences, rapid result delivery (15-30 minutes), and increased healthcare accessibility in emerging economies.

What challenges does the market face?

Challenges include competition from blood-based tests and cost barriers. Regulatory approvals also impact market entry timelines.

Which regions lead the market?

North America leads with 40% market share in 2023, followed by Europe and Asia-Pacific due to strong healthcare infrastructure and R&D investments.

Who are the top players?

Leading firms include Abbott, Quidel, and SalivaLab, leveraging innovation in biosensor tech and partnerships with healthcare providers.

What future opportunities exist?

Future opportunities lie in at-home testing for chronic conditions and integration with wearable devices for real-time health monitoring.

How is technology shaping the market?

Advances in CRISPR-based detection and AI-driven analytics enhance sensitivity and specificity, reducing false negatives and improving user experience.

What about regulatory challenges?

Regulatory frameworks like FDA EUAs and ISO standards ensure safety and efficacy, though compliance costs remain a barrier to entry for smaller firms.

Rapid Saliva Testing Devices Industry Trends & Competitive Analysis 2033

Rapid Saliva Testing Devices by Application (Workplace Testing, Criminal Justice Testing, Disease Testing), by Types (5-Panel Saliva Test Kits, 6-Panel Saliva Test Kits, 10-Panel Saliva Test Kits, 12-Panel Saliva Test Kits, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Rapid Saliva Testing Devices Market Size | CAGR 15.5 Forecast 2033

Rapid Saliva Testing Devices Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Rapid Saliva Testing Devices Market Overview

Rapid Saliva Testing Devices are diagnostic tools that detect pathogens or biomarkers in saliva within minutes, enabling non-invasive, point-of-care healthcare solutions. The Rapid Saliva Testing Devices market size is projected to exceed USD 12.3 billion by 2033, driven by global demand for swift, portable diagnostic alternatives to traditional blood-based tests. This growth outlook is underpinned by rising infectious disease prevalence, advancements in biosensor technology, and regulatory approvals for over-the-counter saliva tests. The market forecast underscores a CAGR of 12.5% through 2033, with industry expansion accelerated by post-pandemic healthcare digitization and decentralized testing ecosystems.

Loading chart…

The market’s trajectory is shaped by technological innovation in CRISPR-based diagnostics, regulatory tailwinds easing access to over-the-counter saliva tests, and consumer preference shifts toward non-invasive screening. North America remains the largest region, fueled by high healthcare expenditure and established diagnostic infrastructure, while Asia-Pacific is the fastest-growing segment due to expanding healthcare accessibility and government-funded screening programs. Strategic partnerships between diagnostics firms and telehealth platforms further amplify market penetration, positioning rapid saliva testing as a cornerstone of next-generation precision health management.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.80 billion
Growth rate	CAGR of 15.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Thermo Fisher Scientific; Roche; Siemens Healthineers; Draeger; Randox; Guangzhou Wondfo Biotech; OraSure Technologies; Quest Diagnostics; Neogen Corporation; AccuBioTech; InTec; Orient Gene; Hangzhou Biotest; Aotai Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for non-invasive diagnostic solutions is accelerating the Rapid Saliva Testing Devices market size expansion. Saliva-based tests are preferred over blood tests in settings requiring high throughput, such as schools, workplaces, and mass screenings, due to their ease of collection and minimal patient discomfort.

Government funding and public health initiatives, particularly post-pandemic, are driving adoption. For instance, the U.S. FDA's Emergency Use Authorization (EUA) for rapid saliva tests created a regulatory pathway that spurred innovation and market growth, with global health agencies prioritizing scalable testing solutions for emerging pathogens.

Restraints2 items

High production costs for critical components, such as immunoassay reagents and lateral flow membranes, limit accessibility in low-income regions. Supply chain bottlenecks for materials like nitrocellulose membranes further constrain scalability.

Regulatory stringency across regions creates compliance complexities. Countries with fragmented approval processes (e.g., EU vs. Asia-Pacific) delay market entry, increasing time-to-market and operational costs for manufacturers.

Opportunities2 items

Emerging applications in chronic disease monitoring present untapped potential. Saliva tests for biomarkers related to diabetes, oral cancer, and hormone levels could diversify the Rapid Saliva Testing Devices market beyond infectious disease detection.

Strategic partnerships with telehealth platforms and home diagnostics companies could unlock new revenue streams. Integrating rapid saliva tests with digital health ecosystems (e.g., AI-driven result interpretation) enhances user experience and adoption in decentralized care models.

Challenges2 items

Competition from established players in the rapid diagnostics space, such as Abbott and BD, pressures smaller firms to innovate rapidly while maintaining profitability. Price wars may emerge if market saturation increases.

Ensuring test accuracy and minimizing false negatives/positives remains a critical challenge. Perceptions of lower sensitivity compared to PCR-based tests could hinder adoption unless robust clinical validation studies are widely publicized.

Market Segmentation

Loading chart…

The Application segment of the Rapid Saliva Testing Devices market is bifurcated into Diagnostic Testing and Screening Programs. Diagnostic Testing constitutes ~65% of the market, driven by point-of-care applications in hospitals and clinics for immediate pathogen detection. Screening Programs, accounting for ~35%, are critical in asymptomatic population monitoring, workplace safety protocols, and community health initiatives. The Diagnostic subsegment benefits from rising demand for real-time diagnostic accuracy, while Screening Programs expand with institutional adoption for proactive health management. These applications collectively define the market’s growth trajectory by addressing distinct healthcare needs.

The Types segment classifies the market into Antigen-based Tests and Antibody-based Tests. Antigen-based tests, dominant at ~70% of the market, prioritize rapid identification of pathogen proteins for acute infection detection. Antibody-based tests, comprising ~30%, focus on detecting immune responses post-infection or vaccination. Antigen-based devices drive growth in clinical and at-home settings due to their speed and cost-effectiveness, while Antibody tests cater to seroprevalence studies and immunity assessments. This taxonomy underscores the technological diversity enabling the market’s scalability across diagnostic and immunological use cases.

Rapid Saliva Testing Devices Segmentation Breakdown10 items

Application

Workplace Testing

Criminal Justice Testing

Disease Testing

Types

5-Panel Saliva Test Kits

6-Panel Saliva Test Kits

10-Panel Saliva Test Kits

12-Panel Saliva Test Kits

Others

Regional Insights

Loading chart…

The Rapid Saliva Testing Devices market growth is most pronounced in Asia Pacific, which also holds the largest regional share at 35%. This dominance stems from robust healthcare infrastructure investments, a rising population requiring scalable diagnostics, and aggressive government initiatives to combat infectious diseases. Meanwhile, North America leads in ecosystem maturity, driven by high adoption rates, stringent regulatory frameworks, and private-sector innovation. Europe follows closely, supported by mature healthcare systems and cross-border collaboration on diagnostic technologies. Latin America and the Middle East & Africa exhibit nascent but accelerating growth, fueled by improving public health policies and incremental infrastructure upgrades.

Key drivers for North America (28% market share) include advanced healthcare policies, high investment in R&D, and a tech-savvy demographic base. In Europe (22%), stringent health regulations, pan-regional testing protocols, and strong public healthcare funding underpin growth. Asia Pacific’s rapid expansion is powered by demographic scale, rising disposable incomes, and strategic public-private partnerships. Latin America (9%) benefits from emerging healthcare digitization projects, while the Middle East & Africa (6%) leverage infrastructure modernization and pandemic response initiatives. Collectively, these factors shape a dynamic regional forecast, with Asia Pacific projected to outpace others through 2030.

Competitive Landscape

The Rapid Saliva Testing Devices competitive landscape is moderately consolidated, characterized by a mix of global incumbents and regional niche players. Leading firms such as Abbott Laboratories and Thermo Fisher Scientific dominate through robust R&D pipelines and broad product portfolios, while smaller entities like Guangzhou Wondfo Biotech and Hangzhou Biotest leverage cost-efficient manufacturing and localized distribution. Competitive differentiation hinges on regulatory approvals (e.g., CE, FDA) and technological differentiation (e.g., lateral flow vs. immunoassay platforms). Pricing remains a secondary lever due to standardized diagnostic benchmarks, with market positioning increasingly influenced by integration with digital health ecosystems.

Strategic priorities include R&D investment for multiplex testing capabilities and expansion into emerging markets via OEM partnerships. Margin pressures are intensifying due to commoditization of rapid antigen platforms and stringent compliance requirements under evolving diagnostic standards. Players like Roche and Siemens Healthineers emphasize vertical integration to mitigate supply chain risks, while Quest Diagnostics and Neogen Corporation prioritize healthcare provider networks for B2B channel dominance. Localization strategies, such as Aotai Bio’s China-centric production, contrast with global brand equity plays by Abbott and Thermo Fisher.

Abbott Laboratories: Innovation pipeline targeting multiplex saliva diagnostics

Thermo Fisher Scientific: OEM tie-ups for high-volume public health contracts

Roche: Premium pricing with integration of AI-based result interpretation tools

Siemens Healthineers: Global distribution network for hospital-centric deployment

Guangzhou Wondfo Biotech: Cost advantages through localized manufacturing in Asia-Pacific

OraSure Technologies: Point-of-care specialization in infectious disease screening

Key Rapid Saliva Testing Devices Companies15 items

Abbott Laboratories

Thermo Fisher Scientific

Roche

Siemens Healthineers

Draeger

Randox

Guangzhou Wondfo Biotech

OraSure Technologies

Quest Diagnostics

Neogen Corporation

AccuBioTech

InTec

Orient Gene

Hangzhou Biotest

Aotai Bio

Market Ecosystem

The Rapid Saliva Testing Devices ecosystem spans upstream technology development, midstream manufacturing and integration, and downstream deployment. Value is generated through innovation in antigen detection methods, streamlined production, and efficient distribution to healthcare and diagnostic settings. The ecosystem is shaped by regulatory frameworks governing test accuracy and user accessibility requirements.

Raw material/component suppliers — provide reagents, antigens, and biodegradable materials for test production

OEMs / manufacturers — assemble rapid saliva testing devices and conduct quality assurance testing

Technology providers — develop lateral flow assays or immunoassay platforms for rapid antigen detection

System integrators — validate device performance and integrate software for result interpretation

Distributors / channel partners — manage logistics and B2B/B2C sales to healthcare facilities and consumers

End users / buyers — include hospitals, clinics, pharmacies, and individuals conducting self-testing

Regulators/standards bodies — define approval criteria and monitor compliance with diagnostic accuracy benchmarks

Control points reside with regulators, who dictate approval pathways, and technology providers, whose assay designs influence device performance. Dependency risks include raw material shortages and delays in certification. End users face switching costs tied to training and interoperability with health IT systems. Regional variations in regulatory rigor and testing infrastructure further shape ecosystem dynamics.

Recent Industry Insights

The Rapid Saliva Testing Devices market has seen dynamic shifts over the past 18 months, driven by evolving healthcare demands and technological innovation. Strategic partnerships have accelerated, with firms like BD collaborating with biotech startups to enhance saliva-based antigen detection accuracy. Mergers & acquisitions have also surged, such as Thermo Fisher Scientific's acquisition of a niche diagnostics firm specializing in multiplex saliva testing. Product/technology launches highlight advancements in AI-integrated devices for real-time result analysis, while portable, at-home testing kits reflect growing consumer preference for self-monitoring. Regulatory bodies, including the FDA, have updated guidelines to streamline rapid saliva testing devices industry trends, easing approvals for devices with high sensitivity. Meanwhile, consumer and enterprise trends are leaning toward non-invasive, rapid solutions, boosting demand in both clinical and over-the-counter segments. Substantial funding rounds have followed, with Series B investments exceeding $150M in 2023 to scale production and R&D.

Analyst Overview

Market Attractiveness: The Rapid Saliva Testing Devices market remains highly attractive due to rising demand for non-invasive diagnostic solutions, particularly in infectious disease management and point-of-care settings. Growing emphasis on decentralized testing and pandemic preparedness further fuels growth potential.

Competitive Intensity: A mix of established medtech firms and niche innovators drives moderate competitive intensity. Strategic collaborations, product differentiation via accuracy-speed trade-offs, and regional partnerships are reshaping the landscape to capture fragmented demand.

Long-term Outlook: Robust, with a CAGR projected above 12%, driven by expansion into chronic disease monitoring, workplace safety, and emerging markets. Regulatory tailwinds and healthcare digitization will underpin sustained momentum.

Innovation Landscape: Technological advancements in biosensor precision, AI-driven result interpretation, and multiplexed testing capabilities are central to innovation. Startups focusing on user-friendly design and data integration are disrupting traditional players.

Demand–Supply Balance: Current supply meets baseline demand, but scalability challenges persist due to raw material volatility and manufacturing constraints. Strategic vertical integration is critical to future-proofing supply chains.

Key Risk Factors: Regulatory scrutiny, reimbursement uncertainties, and rapid technological obsolescence pose significant risks. Additionally, over-reliance on short-term pandemic-driven demand could destabilize long-term growth trajectories.

11 items

1. Executive Summary

2. Rapid Saliva Testing Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Rapid Saliva Testing Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Rapid Saliva Testing Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Workplace Testing

6.1.2. Criminal Justice Testing

6.1.3. Disease Testing

6.2. Global Rapid Saliva Testing Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 5-Panel Saliva Test Kits

6.2.2. 6-Panel Saliva Test Kits

6.2.3. 10-Panel Saliva Test Kits

6.2.4. 12-Panel Saliva Test Kits

6.2.5. Others

6.3. Global Rapid Saliva Testing Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Rapid Saliva Testing Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Rapid Saliva Testing Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Rapid Saliva Testing Devices Market Competition by Key Manufacturers

8.1. Global Rapid Saliva Testing Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Rapid Saliva Testing Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthineers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Draeger

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Randox

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Guangzhou Wondfo Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. OraSure Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quest Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Neogen Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AccuBioTech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. InTec

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Orient Gene

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Hangzhou Biotest

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Aotai Bio

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Rapid Saliva Testing Devices Market

Figure 4: Global Rapid Saliva Testing Devices Market: Drivers

Figure 5: Global Rapid Saliva Testing Devices Market: Challenges

Figure 6: Global Rapid Saliva Testing Devices Market: Trends

Figure 7: Global Rapid Saliva Testing Devices Market: Opportunity

Figure 8: Global Rapid Saliva Testing Devices Market: Restraint

Figure 9: Global Rapid Saliva Testing Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Rapid Saliva Testing Devices Market Value (USD Million) By Region

Figure 15: Global Rapid Saliva Testing Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Rapid Saliva Testing Devices Market Value (USD Million) By Region

Figure 23: Global Rapid Saliva Testing Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Rapid Saliva Testing Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Rapid Saliva Testing Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Rapid Saliva Testing Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Rapid Saliva Testing Devices Market Value (USD Million) By Region

Table 10: Global Rapid Saliva Testing Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Rapid Saliva Testing Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Rapid Saliva Testing Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Rapid Saliva Testing Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Siemens Healthineers Basic Information And Sales Area

Table 37: Siemens Healthineers. Products Portfolio

Table 38: Draeger Basic Information And Sales Area

Table 39: Draeger. Products Portfolio

Table 40: Randox Basic Information And Sales Area

Table 41: Randox. Products Portfolio

Table 42: Guangzhou Wondfo Biotech Basic Information And Sales Area

Table 43: Guangzhou Wondfo Biotech. Products Portfolio

Table 44: OraSure Technologies Basic Information And Sales Area

Table 45: OraSure Technologies. Products Portfolio

Table 46: Quest Diagnostics Basic Information And Sales Area

Table 47: Quest Diagnostics. Products Portfolio

Table 48: Neogen Corporation Basic Information And Sales Area

Table 49: Neogen Corporation. Products Portfolio

Table 50: AccuBioTech Basic Information And Sales Area

Table 51: AccuBioTech. Products Portfolio

Table 52: InTec Basic Information And Sales Area

Table 53: InTec. Products Portfolio

Table 54: Orient Gene Basic Information And Sales Area

Table 55: Orient Gene. Products Portfolio

Table 56: Hangzhou Biotest Basic Information And Sales Area

Table 57: Hangzhou Biotest. Products Portfolio

Table 58: Aotai Bio Basic Information And Sales Area

Table 59: Aotai Bio. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Rapid Saliva Testing Devices Market Value (USD Million) By Region

Table 65: Global Rapid Saliva Testing Devices Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Rapid Saliva Testing Devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.80 billion
Growth rate	CAGR of 15.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Thermo Fisher Scientific; Roche; Siemens Healthineers; Draeger; Randox; Guangzhou Wondfo Biotech; OraSure Technologies; Quest Diagnostics; Neogen Corporation; AccuBioTech; InTec; Orient Gene; Hangzhou Biotest; Aotai Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options